SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (1331)1/31/1998 1:04:00 AM
From: Sigmund  Read Replies (1) | Respond to of 1894
 
Re Cymet it makes me wonder about the patent question. What patents does NeoPath have? There apparently is a patent dispute between NeoPath and Neuromedical. Where does Cymet fit in?

How does this impact ACMI? It has never been clear to me how ACMI and NeoPath differ in their technology in this area. I understand that the process ACMI recommends is to not automatically screen out any slide or any sector of any slide but to provide guidance to the techs on where to look. But the algorithms are possibly the same. The claims are different.

If NeoPath does not really have a lock on the technology through their patents, it seems to me that this is a commodity. I made the point in an earlier post that the technology here is nothing special but simply a new use for machine vision technology in existence for at least fifteen years and probably more.

Quite frankly I think that ACMI is better positioned than NeoPath (except for the patent issue) because the information technology aspects of such an integrated system are more challenging technology wise than the relatively simple task of differentiating one type of cell from another.

This goes to the question of lab economics. I don't think that the task of reading a slide can represent more than $2 assuming labor costs of $25 per hour and processing 100 slides per day per tech (adjust as you see fit). The bulk of the cost is probably associated with preparing the slides to be read, logging them in, reporting the results, quality control, calibrating machines, ordering supplies, storing the slides, maintaining a database of results, billing etc. This probably accounts for the majority of the costs and ACMI is better positioned to address these costs.



To: Cisco who wrote (1331)1/31/1998 1:22:00 AM
From: Frank Buck  Read Replies (2) | Respond to of 1894
 
Cisco,

This area is really starting to look like a Cecil B. DeMille Production with a cast of thousands coming soon to a theatre (or lab) near you!

On the auto auto/assisted device side we have:

AccuMed<*><*>Morphometrix<*><*>NeoPath<*><*>Neuromedical<*><*>

On the liquid based slide preparations:

AutoCyte<*><*><*><*>Cytyc<*><*><*><*>Mono Gen<*><*><*><*>

Then we have three offshoots

Digene<*><*><*><*>Trylon<*><*><*><*>Cytology West<*><*><*><*>

Trylon and Cytology West are privately held. Trylon had news on the 28th regarding their Speculite Technology. Cytology West was mentioned sometime ago in an AutoCyte press release. I can't find anything out about Cytology West. Digene had big news in Europe yesterday. Here is a better visual scorecard link which includes your two new cast members: Morphometrix and Mono Gen;

cytopathnet.org

Trylon's Speculite, Digene's DNA Assay, and Cytology West ???? are free agents for the time being.

Here is another link that is supposed to show the beauty of a ThinPrep slide. Nice clear photos;

erinet.com

Frank


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News